RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $102 | +2.0% | 13,341 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $100 | +3.1% | 13,341 | -8.2% | 0.00% | 0.0% |
| Q1 2023 | $97 | -29.2% | 14,529 | -18.5% | 0.00% | 0.0% |
| Q4 2022 | $137 | -99.9% | 17,823 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $190,000 | +32.9% | 17,823 | +1.7% | 0.00% | +100.0% |
| Q2 2022 | $143,000 | +16.3% | 17,517 | +1.9% | 0.00% | 0.0% |
| Q1 2022 | $123,000 | -80.6% | 17,187 | -53.6% | 0.00% | -50.0% |
| Q4 2021 | $634,000 | – | 37,068 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $79,603,360 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $45,449,568 | 43.00% |
| MIC Capital Management UK LLP | 8,451,758 | $64,655,952 | 14.74% |
| MV Management XI, L.L.C. | 788,762 | $6,034,029 | 10.04% |
| ArchPoint Investors | 1,047,386 | $8,012,503 | 3.06% |
| Connective Portfolio Management, LLC | 33,000 | $252,000 | 0.77% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,335,132 | $17,863,760 | 0.70% |
| Diametric Capital, LP | 136,331 | $1,042,932 | 0.44% |
| ARK Investment Management | 6,876,598 | $52,605,973 | 0.40% |
| ALLEN OPERATIONS LLC | 217,657 | $1,665,076 | 0.37% |